Press Releases and Blog
Blog
Fortune By: Tony LoSasso March 4, 2026 President Trump has repeatedly promised to bring down prescription drug prices. His Republican Congress says it shares that goal. But tucked inside the recently passed 2026 Consolidated Appropriations Act is a restructuring of the drug market that makes lower prices less likely, not more. How does […]
PharmaVoice By Alivia Kaylor February 27, 2026 For over a decade, pharmacy benefit managers have been in the hot seat, absorbing the bulk of Washington’s bipartisan scrutiny over rising prescription drug costs. Now, the pricing pendulum is swinging back in pharma’s direction. Sweeping reforms in the Consolidated Appropriations Act of 2026, signed into law […]
The enactment of PBM reforms last month was a victory for the big drugmaker’s diversion campaign. But now that PBM reform – and the distractions – is done it’s important to reaffirm the immense value PBMs provide patients, employers, and the entire health care system in order to prevent further unintended consequences for employers and patients. An analysis by George S. […]
At a House Energy and Commerce subcommittee hearing last week, the full pharmaceutical drug supply chain testified, including a group that professes to represent employer interests. In one of the more fascinating exchanges, a member of the subcommittee sought to better understand how rebates become part of employer contracts with their pharmacy benefit manager (PBM). […]
Congress recently enacted government mandates on employers and pharmacy benefit managers (PBMs) – the ones who counter the pricing power of Big Pharma and deliver savings for American patients and employers. This intervention, dictating contract terms for employers and PBMs, was the result of a years-long campaign by Big Pharma to distract attention and keep […]
Earlier this month, the president signed into law significant new mandates on employers and pharmacy benefit managers – full PBM transparency, full rebate pass-through, Medicare delinking. These were big wins for the big drugmakers who’ve long invested heavily in diverting attention away from their role in the ridiculous prices charged for prescription drugs in America. […]
Press Releases
PBMs are transparent and reduce drug costs in New Jersey The Pharmaceutical Care Management Association (PCMA) issued the following statement on New Jersey Governor Mikie Sherrill’s budget address: “The governor’s remarks today about pharmacy benefit managers (PBMs) are simply untrue and misleading to New Jersey patients, and it is imperative to correct the record. The […]
Now, Congress Should Make Biosimilars Interchangeable (Washington, D.C.) – The Trump Administration is taking action to increase access to biosimilars. Congress can take the administration’s lead and entirely eliminate the interchangeability designation for biosimilars. In response to the new draft guidance, issued yesterday by the Food and Drug Administration, Pharmaceutical Care Management Association President and CEO, David […]
(Washington, D.C) – Several state legislatures and some federal lawmakers have considered a dangerous policy, known as “Forced Pharmacy Closure,” that bars integration between pharmacy benefit managers and pharmacies. If implemented, the result – shutting down hundreds or thousands of pharmacies – would inflict grave economic consequences and put the health of patients at risk, according […]
In his State of the Union address Tuesday night, President Donald Trump spoke about the need to lower drug prices in America, a primary focus of pharmacy benefit manager (PBM) companies. In response, Pharmaceutical Care Management Association President and CEO David Marin released the following statement: “Tonight, President Trump spoke to our shared goal of making health […]
Employers report high satisfaction with drug savings PBMs get and the transparency they provide (Washington, D.C.) — A new survey released today shows American employers are highly satisfied with their pharmacy benefit manager (PBM) relationship. The survey results found PBMs are exceeding employers’ expectations in key performance areas, including the amount of savings they get on […]
(Washington, D.C.) — Today, the Pharmaceutical Care Management Association (PCMA) released new data that provides a snapshot of the health of independent pharmacies in the United States. The findings reveal that the overall number of independent pharmacies in the U.S. grew from 2025 to 2026, according to new data from the National Council for Prescription Drug […]
POLITICO Q&A: PCMA Chief Executive JC Scott
JC Scott and PCMA’s top lobbyist Kristin Bass talk about the criticism facing the PBM industry, how to break through to policymakers and the future of the industry.
PBMs Under Fire at Senate Hearing
“The PBM industry is the only stakeholder in the chain dedicated to seeking lower costs, and we are proud to play that role,” said JC Scott, president and CEO of the Pharmaceutical Care Management Association. “PBMs do that work for the employer, union health plan, and government clients who hire them and most importantly, the patients for whom those plans provide coverage.”
Washington DC’s 500 Most Influential People
JC Scott, Pharmaceutical Care Management Association, President and CEO Scott worked to include a repeal of the last administration’s prescription-drug rebate rule in the Democrats’ reconciliation package.
Part D plans have extra time to prep to apply price concessions at the point of sale
“This extra year will help to reduce disruptions to Medicare beneficiaries by allowing Part D plans time to adjust their pay-for-performance pharmacy contracting,” PCMA said. “In addition, the delay appropriately prevents premiums from increasing in 2023 on top of rising inflation.”
Profit Pump: 100 years after first patient uses insulin, out-of-pocket costs continue to climb
“We believe the key to reducing drug costs is increasing competition, including for insulin products,” said the Pharmaceutical Care Management Association (PCMA). “Unfortunately, tactics used by drug manufacturers to avoid competition, including ongoing patent extensions on insulin products, are a significant barrier to getting costs down even further for people with diabetes.”
Drugmakers are the ones that control the cost of insulin
Drug manufacturers have leveraged limited competition in the insulin market to increase the list price of insulin products over the past 10 years. PBMs, on the other hand, are working on behalf of patients to negotiate lower costs and increase access to these needed medications. PBMs have stepped up efforts to help patients living with diabetes afford their medications by introducing new programs to cap, or outright eliminate, out-of-pocket costs on insulin.
Bipartisan lawmakers push for ending insulin rebates in drug prices bill
The provision to target rebates drew pushback from the Pharmaceutical Care Management Association, which represents the PBM industry. The priorities would “provide drug manufacturers additional opportunities to maximize revenues by gaming which products to roll back to 2006 prices to avoid discounting, and which products to keep at 2022 pricing,” the group said in a statement to Fierce Healthcare. “It would do little to reduce costs for patients.
Mayo-backed nonprofit Civica Rx plans to make low-cost insulin starting in 2024
Greg Lopes, a spokesman for the Pharmaceutical Care Management Association, said PBMs believe the key to lowering costs for insulin, and drugs more broadly, is more competition among manufacturers. He said drug companies have avoided doing that through tactics like extending patents on insulin products.
The biggest PBMs are handling more and more of the country’s drug price negotiations
“We are simply seeing more activity in the pharmacy space, which is leading to more business,” JC Scott, the head of the Pharmaceutical Care Management Association, the primary lobbying group for PBMs, told STAT. “There’s more demand for PBM services as a result of that.”
Pharmacy Benefit Managers Are The Wrong Target In Biden’s Quest To Reduce Drug Prices
Pharmacy benefit managers (PBMs) act as a necessary and effective intermediary between pharmaceutical manufacturers and health insurers. In essence, they counter the market power of a pharmaceutical company by creating a formulary—a list of drugs that the PBM will provide for the patients it covers—and negotiating steep volume discounts for these drugs by dint of their scale.
